Literature DB >> 15622323

C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.

Keith Henry1, Douglas Kitch, Michael Dube, Robert Zackin, Robert A Parker, Dennis Sprecher, Scott Hammer, Judith Currier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15622323

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  15 in total

1.  Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy.

Authors:  John R Koethe; Aihua Bian; Ayumi K Shintani; M Sean Boger; Valerie J Mitchell; Husamettin Erdem; Todd Hulgan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

2.  Cardiovascular and Endothelial Disease in HIV Infection.

Authors:  Michelle S Cespedes; Judith A Aberg
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Brief Report: Circulating Markers of Immunologic Activity Reflect Adiposity in Persons With HIV on Antiretroviral Therapy.

Authors:  John R Koethe; Cathy A Jenkins; Briana D Furch; Jordan E Lake; Louise Barnett; Cindy C Hager; Rita Smith; Todd Hulgan; Bryan E Shepherd; Spyros A Kalams
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

4.  Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

Authors:  Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey
Journal:  J Infect Dis       Date:  2015-01-12       Impact factor: 5.226

5.  Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

Authors:  Cecilia M Shikuma; Heather J Ribaudo; Yu Zheng; Roy M Gulick; William A Meyer; Karen T Tashima; Barbara Bastow; Daniel R Kuritzkes; Marshall J Glesby
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

6.  Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

Authors:  Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

7.  Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.

Authors:  V H Barbai; E Ujhelyi; J Szlávik; I Vietorisz; L Varga; E Fey; G Füst; D Bánhegyi
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

8.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Paul E Sax
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

Review 9.  Adipose tissue and immune function: a review of evidence relevant to HIV infection.

Authors:  John R Koethe; Todd Hulgan; Kevin Niswender
Journal:  J Infect Dis       Date:  2013-07-21       Impact factor: 5.226

10.  C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting.

Authors:  Paul K Drain; Roland Kupka; Gernard I Msamanga; Willy Urassa; Ferdinand Mugusi; Wafaie W Fawzi
Journal:  AIDS       Date:  2007-10-01       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.